[go: up one dir, main page]

RU2018105494A3 - - Google Patents

Download PDF

Info

Publication number
RU2018105494A3
RU2018105494A3 RU2018105494A RU2018105494A RU2018105494A3 RU 2018105494 A3 RU2018105494 A3 RU 2018105494A3 RU 2018105494 A RU2018105494 A RU 2018105494A RU 2018105494 A RU2018105494 A RU 2018105494A RU 2018105494 A3 RU2018105494 A3 RU 2018105494A3
Authority
RU
Russia
Application number
RU2018105494A
Other versions
RU2018105494A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018105494A publication Critical patent/RU2018105494A/ru
Publication of RU2018105494A3 publication Critical patent/RU2018105494A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018105494A 2015-07-15 2016-07-14 Улучшенные системы доставки наночастиц RU2018105494A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562192973P 2015-07-15 2015-07-15
US62/192,973 2015-07-15
US201562252396P 2015-11-06 2015-11-06
US62/252,396 2015-11-06
PCT/US2016/042330 WO2017011685A1 (en) 2015-07-15 2016-07-14 Improved nanoparticle delivery systems

Publications (2)

Publication Number Publication Date
RU2018105494A RU2018105494A (ru) 2019-08-15
RU2018105494A3 true RU2018105494A3 (ru) 2019-12-17

Family

ID=57757767

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018105494A RU2018105494A (ru) 2015-07-15 2016-07-14 Улучшенные системы доставки наночастиц

Country Status (17)

Country Link
US (4) US10285951B2 (ru)
EP (1) EP3322404A4 (ru)
JP (2) JP2018521068A (ru)
KR (1) KR20180029242A (ru)
CN (1) CN107920985B (ru)
AU (2) AU2016294617B2 (ru)
BR (1) BR112018000217A2 (ru)
CA (1) CA2991062C (ru)
CO (1) CO2018000146A2 (ru)
HK (1) HK1251159A1 (ru)
IL (1) IL256797B (ru)
MA (1) MA42458A (ru)
MX (1) MX2018000611A (ru)
RU (1) RU2018105494A (ru)
SG (1) SG10201912394VA (ru)
WO (1) WO2017011685A1 (ru)
ZA (1) ZA201800130B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077439A (zh) 2016-04-29 2023-05-09 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
EP3713547A4 (en) * 2017-11-20 2023-07-19 Icahn School of Medicine at Mount Sinai Inhibiting trained immunity with a therapeutic nanobilogic composition
US20210023017A1 (en) * 2018-03-16 2021-01-28 University Of Massachusetts Yeast cell wall particle encapsulation of biodegradable pro-payloads
KR102088663B1 (ko) * 2018-03-20 2020-03-13 한국세라믹기술원 친수성 및 소수성 약물의 동시 전달을 위한 온도민감성 나노스펀지 플랫폼 및 이의 용도
WO2020123481A1 (en) * 2018-12-10 2020-06-18 Celator Pharmaceuticals Inc. Combination formulations of taxanes and mtor inhibitors
MX2022001083A (es) * 2019-08-13 2022-05-18 Peptinovo Biopharma Inc Micelas lipídicas anfifílicas peptídicas (palm) para tratamiento de neuropatía periférica inducida por quimioterapia relacionada con el tratamiento del cáncer.
AU2021340521A1 (en) * 2020-09-10 2023-05-25 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing pd-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
BR112023018950A2 (pt) 2021-03-19 2024-02-27 Icahn School Med Mount Sinai Composto, composições nanobiológica e farmacêutica, métodos para tratar um distúrbio de proliferação celular, para tratar sepse e para ativar um receptor nod2, processo para fabricação de uma composição nanobiológica e kit
WO2025199353A1 (en) * 2024-03-21 2025-09-25 Purdue Research Foundation Nanoparticulate formulations and foliar administration thereof in the treatment and prevention of citrus greening disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60216305T2 (de) * 2001-10-03 2007-07-05 Celator Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Abgabe von Arzneimittelkombinationen
JP2005518354A (ja) 2001-11-19 2005-06-23 コントロール・デリバリー・システムズ・インコーポレイテッド コドラッグを含有する医薬組成物
JP2006514088A (ja) 2003-02-20 2006-04-27 ユニバーシティー オブ コネティカット ヘルス センター 癌および感染症の治療における熱ショックタンパク質またはα−2−マクログロブリンを含む組成物の使用方法
CA2574767C (en) * 2004-07-19 2015-02-17 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
KR20080009196A (ko) * 2005-04-12 2008-01-25 위스콘신 얼럼나이 리서어치 화운데이션 중합체 및 패신저 약물의 마이셀 조성물
ES2535217T3 (es) * 2007-11-28 2015-05-07 Celator Pharmaceuticals, Inc. Sistema mejorado de administración de taxano
CN102378626B (zh) * 2009-03-30 2014-05-14 天蓝制药公司 聚合物-药剂缀合物、颗粒、组合物和相关使用方法
WO2011060328A1 (en) 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
JP5655147B2 (ja) * 2010-08-20 2015-01-14 セルリアン・ファーマ・インコーポレイテッド 治療用ペプチド−ポリマーの複合体、粒子、組成物および関連の方法
KR20130116291A (ko) * 2010-11-19 2013-10-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Braf 억제제를 이용한 치료 방법
MX2013012598A (es) * 2011-04-29 2014-08-18 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para eliminar linfocitos t efectores específicos para un antígeno.
WO2012166923A2 (en) * 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
DE102011109374A1 (de) * 2011-08-04 2013-02-07 Bock 1 Gmbh & Co. Kg Stuhl mit Wippmechanik
KR20190143491A (ko) * 2014-06-30 2019-12-30 타베다 세라퓨틱스, 인코포레이티드 표적화된 콘주게이트 및 입자 및 그것의 제형

Also Published As

Publication number Publication date
US20210052508A1 (en) 2021-02-25
US10285951B2 (en) 2019-05-14
RU2018105494A (ru) 2019-08-15
CO2018000146A2 (es) 2018-04-19
AU2016294617A1 (en) 2018-01-25
MA42458A (fr) 2018-05-23
JP2018521068A (ja) 2018-08-02
CA2991062A1 (en) 2017-01-19
CA2991062C (en) 2023-06-20
US20180207104A1 (en) 2018-07-26
AU2016294617B2 (en) 2021-09-16
EP3322404A4 (en) 2019-03-20
MX2018000611A (es) 2018-09-06
HK1251159A1 (zh) 2019-01-25
US11413253B2 (en) 2022-08-16
US20240366519A1 (en) 2024-11-07
EP3322404A1 (en) 2018-05-23
ZA201800130B (en) 2018-12-19
AU2021286353A1 (en) 2022-01-20
SG10201912394VA (en) 2020-02-27
IL256797A (en) 2018-06-28
BR112018000217A2 (pt) 2018-09-04
KR20180029242A (ko) 2018-03-20
US20190209484A1 (en) 2019-07-11
JP2022033751A (ja) 2022-03-02
CN107920985A (zh) 2018-04-17
IL256797B (en) 2021-05-31
WO2017011685A1 (en) 2017-01-19
CN107920985B (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
RU2018105494A3 (ru)
BR112017028060A2 (ru)
BR112018010258A2 (ru)
AU2022228198B1 (ru)
BE2015C047I2 (ru)
BE2015C044I2 (ru)
BR0111373B1 (ru)
BR0009942B1 (ru)
BR0000695B1 (ru)
CN303067612S (ru)
CN303067480S (ru)
BR0000126B1 (ru)
CN303069896S (ru)
CN303066192S (ru)
CN303066182S (ru)
BR0001536B1 (ru)
CN303070694S (ru)
BR0000763F1 (ru)
CN303071517S (ru)
BR0008789B1 (ru)
BR0314770B1 (ru)
BR0308527B1 (ru)
BR0216116B1 (ru)
BR0212408B1 (ru)
BR0007834B1 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210301